FDA Commissioner Gottlieb on agency's efforts to increase the availability of naloxone

FDA Commissioner Scott Gottlieb says the agency is looking at new ways to increase the availability of naloxone. FDA on Tuesday announced an upcoming 2-day advisory committee meeting in December to solicit input and advice on strategies to increase the availability of naloxone products intended for use in the community.

FDA Commissioner Scott Gottlieb says the agency is looking at new ways to increase the availability of naloxone. FDA on Tuesday announced an upcoming 2-day advisory committee meeting in December to solicit input and advice on strategies to increase the availability of naloxone products intended for use in the community. External advisors from FDA's Anesthetic and Analgesic Drug Products and the Drug Safety and Risk Management Advisory Committees will be asked to consider various options for increasing access to naloxone. The agency will also consider whether naloxone should be co-prescribed with all or some opioid prescriptions to reduce the risk of overdose death. Gottlieb says there will also be discussions on the potential development of OTC naloxone at the upcoming meeting.